肾母细胞瘤1（WT1）：癌症疫苗。
Wilms' Tumor 1 (WT1): The Vaccine for Cancer.
作者信息
Hein Kyaw Zaw, Yao Shuyang, Fu Siqing
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Immunother Precis Oncol. 2020 Nov 12;3(4):165-171. doi: 10.36401/JIPO-20-12. eCollection 2020 Nov.
Abstract
Vaccines have been used to fight and protect against infectious diseases for centuries. With the emergence of immunotherapy in cancer treatment, researchers began investigating vaccines that could be used against cancer, especially against tumors that are resistant to conservative chemotherapy, surgery, and radiotherapy. The Wilms' tumor 1 (WT1) protein is immunogenic, has been detected in almost all types of malignancies, and has played a significant role in prognosis and disease monitoring. In this article, we review recent developments in the treatment of various types of cancers with the WT1 cancer vaccine; we also discuss theoretic considerations of various therapeutic approaches, which were based on preclinical and clinical data.
摘要
几个世纪以来，疫苗一直被用于对抗和预防传染病。随着免疫疗法在癌症治疗中的出现，研究人员开始研究可用于对抗癌症的疫苗，尤其是针对那些对传统化疗、手术和放疗具有抗性的肿瘤。肾母细胞瘤1（WT1）蛋白具有免疫原性，几乎在所有类型的恶性肿瘤中都能检测到，并且在预后和疾病监测中发挥了重要作用。在本文中，我们回顾了WT1癌症疫苗在各类癌症治疗中的最新进展；我们还讨论了基于临床前和临床数据的各种治疗方法的理论考量。
相似文献
1
Wilms' Tumor 1 (WT1): The Vaccine for Cancer.肾母细胞瘤1（WT1）：癌症疫苗。
J Immunother Precis Oncol. 2020 Nov 12;3(4):165-171. doi: 10.36401/JIPO-20-12. eCollection 2020 Nov.
2
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.WT1 肽疫苗治疗血液系统恶性肿瘤：从 CTL 表位鉴定到包括治愈策略在内的临床研究最新进展。
Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18.
3
Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.Wilms 瘤 1 靶向癌症疫苗：最新进展与未来展望。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2296735. doi: 10.1080/21645515.2023.2296735. Epub 2023 Dec 26.
4
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.针对造血系统恶性肿瘤和实体癌的WT1肽癌症疫苗的研发。
Curr Med Chem. 2006;13(20):2345-52. doi: 10.2174/092986706777935104.
5
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.针对血液系统恶性肿瘤和实体瘤患者的 Wilms 瘤蛋白 1（WT1）的主动特异性免疫治疗：来自早期临床试验的经验。
Oncologist. 2012;17(2):250-9. doi: 10.1634/theoncologist.2011-0240. Epub 2012 Jan 30.
6
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.WT1肽疫苗作为恶性肿瘤“癌症抗原衍生肽”免疫疗法的范例：通过接种单一WT1肽成功诱导抗癌效果。
Anticancer Agents Med Chem. 2009 Sep;9(7):787-97. doi: 10.2174/187152009789056958. Epub 2009 Sep 1.
7
WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.用于造血系统恶性肿瘤和实体癌患者的WT1肽癌症疫苗。
ScientificWorldJournal. 2007 May 29;7:649-65. doi: 10.1100/tsw.2007.119.
8
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.WT1（威尔姆斯瘤基因）肽疫苗诱导WT1特异性细胞毒性T淋巴细胞及由此导致的癌症消退。
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13.
9
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.使用表达截短型威尔姆斯瘤蛋白（WT1）的腺病毒疫苗诱导WT1特异性抗肿瘤免疫。
Clin Cancer Res. 2009 Apr 15;15(8):2789-96. doi: 10.1158/1078-0432.CCR-08-2589. Epub 2009 Apr 7.
10
[Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].针对恶性脑肿瘤患者的靶向肾母细胞瘤1基因产物的免疫疗法
Brain Nerve. 2009 Jul;61(7):805-14.
引用本文的文献
1
Immunotherapy for High-Grade Gliomas.高级别胶质瘤的免疫治疗
Cancers (Basel). 2025 May 31;17(11):1849. doi: 10.3390/cancers17111849.
2
Cancer immunotherapy of Wilms tumor: a narrative review.Wilms 瘤的癌症免疫疗法：叙述性综述。
Future Oncol. 2024;20(30):2293-2302. doi: 10.1080/14796694.2024.2386929. Epub 2024 Sep 5.
3
Crosstalk between genomic variants and DNA methylation in FLT3 mutant acute myeloid leukemia.FLT3突变型急性髓系白血病中基因组变异与DNA甲基化之间的相互作用
Brief Funct Genomics. 2025 Jan 15;24. doi: 10.1093/bfgp/elae028.
4
Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers.探索唾液腺癌免疫治疗中的免疫效应和新型免疫佐剂。
Cancers (Basel). 2024 Mar 19;16(6):1205. doi: 10.3390/cancers16061205.
5
Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP.Wilms' 肿瘤 1 （WT1）抗原在卡波西肉瘤中过表达，并受 KSHV vFLIP 调节。
PLoS Pathog. 2024 Jan 8;20(1):e1011881. doi: 10.1371/journal.ppat.1011881. eCollection 2024 Jan.
6
Glioblastoma vaccines: past, present, and opportunities.胶质母细胞瘤疫苗：过去、现在和未来的机遇。
EBioMedicine. 2024 Feb;100:104963. doi: 10.1016/j.ebiom.2023.104963. Epub 2024 Jan 5.
7
Advances in immunotherapy for biliary tract cancers.胆管癌免疫治疗的进展
Chin Med J (Engl). 2024 Mar 5;137(5):524-532. doi: 10.1097/CM9.0000000000002759. Epub 2023 Aug 29.
8
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy.癌症免疫治疗分子机制的最新进展
Cancers (Basel). 2023 May 11;15(10):2721. doi: 10.3390/cancers15102721.
9
High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients' samples.在多发性骨髓瘤和浆细胞瘤中 Wilms 肿瘤 1 表达的高发生率：142 例亚洲患者样本的队列研究。
Pathol Oncol Res. 2023 Jan 24;29:1610844. doi: 10.3389/pore.2023.1610844. eCollection 2023.
本文引用的文献
1
Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.肾母细胞瘤1肽脉冲树突状细胞疫苗联合传统化疗用于头颈癌患者的I/II期初步研究
Ther Apher Dial. 2019 Jun;23(3):279-288. doi: 10.1111/1744-9987.12831. Epub 2019 Jun 6.
2
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.WT1 肽-HLA Ⅰ类和Ⅱ类鸡尾酒疫苗治疗复发性恶性脑胶质瘤的Ⅰ期临床研究。
Cancer Immunol Immunother. 2019 Feb;68(2):331-340. doi: 10.1007/s00262-018-2274-1. Epub 2018 Nov 14.
3
Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.多模态治疗联合 WT1 靶向树突状细胞疫苗治疗胰腺癌患者的长期生存。
Hum Vaccin Immunother. 2019;15(2):397-406. doi: 10.1080/21645515.2018.1524238. Epub 2018 Oct 12.
4
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.儿科恶性肿瘤免疫治疗的机遇与挑战：简明快照。
Eur J Pediatr. 2017 Sep;176(9):1163-1172. doi: 10.1007/s00431-017-2982-0. Epub 2017 Aug 12.
5
Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.异基因肾母细胞瘤1树突状细胞疫苗接种和供体淋巴细胞输注后血液系统恶性肿瘤及移植后复发患者免疫反应的诱导
Biol Blood Marrow Transplant. 2016 Dec;22(12):2149-2154. doi: 10.1016/j.bbmt.2016.08.028. Epub 2016 Sep 12.
6
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.树突状细胞作为癌症免疫疗法的药理学工具。
Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456.
7
Therapeutic cancer vaccines.治疗性癌症疫苗
J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27.
8
Classification of current anticancer immunotherapies.当前抗癌免疫疗法的分类。
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.
9
Immune-based therapies for childhood cancer.儿童癌症的免疫疗法。
Nat Rev Clin Oncol. 2014 Dec;11(12):693-703. doi: 10.1038/nrclinonc.2014.177. Epub 2014 Oct 28.
10
Clinical use of dendritic cells for cancer therapy.树突状细胞在癌症治疗中的临床应用。
Lancet Oncol. 2014 Jun;15(7):e257-67. doi: 10.1016/S1470-2045(13)70585-0.
Zotero 插件